Nisa Investment Advisors LLC Reduces Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 41.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 11,867 shares of the company’s stock after selling 8,476 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Janux Therapeutics were worth $635,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Avanza Fonder AB purchased a new stake in Janux Therapeutics in the fourth quarter valued at $139,000. Franklin Resources Inc. increased its position in shares of Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after purchasing an additional 7,442 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Janux Therapeutics in the 3rd quarter valued at about $940,000. Finally, Geode Capital Management LLC grew its stake in Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JANX. HC Wainwright lifted their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus lifted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Scotiabank raised their price target on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Finally, Leerink Partners upped their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Stock Down 3.8 %

Shares of NASDAQ:JANX opened at $41.88 on Wednesday. The business has a fifty day simple moving average of $51.90 and a 200-day simple moving average of $48.47. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $71.71. The company has a market cap of $2.20 billion, a P/E ratio of -35.79 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The business’s revenue for the quarter was down 82.6% on a year-over-year basis. Sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the transaction, the chief executive officer now owns 257,054 shares in the company, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 83,334 shares of company stock valued at $4,731,520 over the last ninety days. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.